Imugene Limited (IUGNF)
OTCMKTS · Delayed Price · Currency is USD
0.1737
-0.0401 (-18.74%)
Aug 1, 2025, 12:35 PM EDT
Bally's Revenue
Imugene had revenue of 1.26M AUD in the half year ending December 31, 2024, a decrease of -73.86%. This brings the company's revenue in the last twelve months to -1.84M, down -112.24% year-over-year. In the fiscal year ending June 30, 2024, Imugene had annual revenue of 4.97M, down -57.80%.
Revenue (ttm)
-1.84M AUD
Revenue Growth
-112.24%
P/S Ratio
-40.88
Revenue / Employee
-367.92K AUD
Employees
5
Market Cap
46.54M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 4.97M | -6.81M | -57.80% |
Jun 30, 2023 | 11.78M | -1.19M | -9.19% |
Jun 30, 2022 | 12.97M | 5.74M | 79.35% |
Jun 30, 2021 | 7.23M | 3.10M | 74.94% |
Jun 30, 2020 | 4.13M | 6.56K | 0.16% |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Imugene News
- 19 days ago - Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL - PRNewsWire
- 20 days ago - Imugene set to dazzle market with new clinical data, cash call - The Australian Financial Review
- 1 year ago - Bile Tract Cancer expansion study opens following clearance of Imugene's MAST trial high dose cohort - GlobeNewsWire
- 1 year ago - Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 - GlobeNewsWire
- 1 year ago - Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts - GlobeNewsWire
- 1 year ago - Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium - Accesswire
- 1 year ago - NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments - PRNewsWire
- 3 years ago - City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors - Business Wire